Europe Active Pharmaceutical Ingredients Market Size, Status and Forecast 2014-2026

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • An active ingredient (AI) is the ingredient in a pharmaceutical drug that is biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active are also used in medicine, and the term active substance may be used for natural products. Some medication products may contain more than one active ingredient. The traditional word for the API is pharmacon or pharmakon which originally denoted a magical substance or drug.

    The Active Pharmaceutical Ingredients market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.4% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Active Pharmaceutical Ingredients Market Segmentations:

    By Player:

    • Aurobindo Pharma

    • Shandong Xinhua Pharmaceutical

    • Northeast Pharm

    • BASF

    • Novartis

    • LKPC

    • Aspen

    • Sun Pharmaceutical Industries

    • Teva

    • NCPC

    • Pfizer

    • Mylan

    • Zhejiang NHU

    • Bayer

    • Zhejiang Medicine

    • Hisun Pharmaceutical

    • Huahai Pharmaceutical

    • AbbVie

    • DSM

    • Harbin Pharmaceutical

    By Type:

    • Synthetic APIs

    • Biotech APIs

    By End-User:

    • Hospitals/Clinics

    • Household

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Active Pharmaceutical Ingredients Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Active Pharmaceutical Ingredients Market Size and Growth Rate of Synthetic APIs from 2014 to 2026

    • 1.3.2 Europe Active Pharmaceutical Ingredients Market Size and Growth Rate of Biotech APIs from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Active Pharmaceutical Ingredients Market Size and Growth Rate of Hospitals/Clinics from 2014 to 2026

    • 1.4.2 Europe Active Pharmaceutical Ingredients Market Size and Growth Rate of Household from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Active Pharmaceutical Ingredients Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Active Pharmaceutical Ingredients by Major Types

      • 3.4.1 Market Size and Growth Rate of Synthetic APIs

      • 3.4.2 Market Size and Growth Rate of Biotech APIs

    4 Segmentation of Active Pharmaceutical Ingredients Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Active Pharmaceutical Ingredients by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Hospitals/Clinics for Construction

      • 4.4.2 Market Size and Growth Rate of Household for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Active Pharmaceutical Ingredients Production Analysis by Top Regions

    • 5.2 Europe Active Pharmaceutical Ingredients Consumption Analysis by Top Regions

    • 5.3 Europe Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.3 France Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    6 Product Circulation of Active Pharmaceutical Ingredients Market among Top Countries

    • 6.1 Top 5 Export Countries in Active Pharmaceutical Ingredients Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Active Pharmaceutical Ingredients Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Active Pharmaceutical Ingredients Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Active Pharmaceutical Ingredients Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Active Pharmaceutical Ingredients Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Active Pharmaceutical Ingredients Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Active Pharmaceutical Ingredients Landscape Analysis

    • 7.1 Germany Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 7.2 Germany Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    8. UK Active Pharmaceutical Ingredients Landscape Analysis

    • 8.1 UK Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 8.2 UK Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    9. France Active Pharmaceutical Ingredients Landscape Analysis

    • 9.1 France Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 9.2 France Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    10. Italy Active Pharmaceutical Ingredients Landscape Analysis

    • 10.1 Italy Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 10.2 Italy Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    11. Spain Active Pharmaceutical Ingredients Landscape Analysis

    • 11.1 Spain Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 11.2 Spain Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    12. Poland Active Pharmaceutical Ingredients Landscape Analysis

    • 12.1 Poland Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 12.2 Poland Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    13. Russia Active Pharmaceutical Ingredients Landscape Analysis

    • 13.1 Russia Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 13.2 Russia Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    14. Switzerland Active Pharmaceutical Ingredients Landscape Analysis

    • 14.1 Switzerland Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 14.2 Switzerland Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    15. Turkey Active Pharmaceutical Ingredients Landscape Analysis

    • 15.1 Turkey Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 15.2 Turkey Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Landscape Analysis by Top Countries

      • 16.3.1 Denmark Active Pharmaceutical Ingredients Market Volume and Growth Rate

      • 16.3.2 Finland Active Pharmaceutical Ingredients Market Volume and Growth Rate

      • 16.3.3 Norway Active Pharmaceutical Ingredients Market Volume and Growth Rate

      • 16.3.4 Sweden Active Pharmaceutical Ingredients Market Volume and Growth Rate

      • 16.3.6 Iceland Active Pharmaceutical Ingredients Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Landscape Analysis by Top Countries

      • 17.3.1 Belgium Active Pharmaceutical Ingredients Market Volume and Growth Rate

      • 17.3.2 Netherlands Active Pharmaceutical Ingredients Market Volume and Growth Rate

      • 17.3.3 Luxembourg Active Pharmaceutical Ingredients Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Landscape Analysis by Top Countries

      • 18.3.1 Estonia Active Pharmaceutical Ingredients Market Volume and Growth Rate

      • 18.3.2 Latvia Active Pharmaceutical Ingredients Market Volume and Growth Rate

      • 18.3.3 Lithuania Active Pharmaceutical Ingredients Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Aurobindo Pharma

      • 19.1.1 Aurobindo Pharma Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Shandong Xinhua Pharmaceutical

      • 19.2.1 Shandong Xinhua Pharmaceutical Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Northeast Pharm

      • 19.3.1 Northeast Pharm Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 BASF

      • 19.4.1 BASF Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Novartis

      • 19.5.1 Novartis Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 LKPC

      • 19.6.1 LKPC Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Aspen

      • 19.7.1 Aspen Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Sun Pharmaceutical Industries

      • 19.8.1 Sun Pharmaceutical Industries Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Teva

      • 19.9.1 Teva Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 NCPC

      • 19.10.1 NCPC Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Pfizer

      • 19.11.1 Pfizer Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Mylan

      • 19.12.1 Mylan Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Zhejiang NHU

      • 19.13.1 Zhejiang NHU Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Bayer

      • 19.14.1 Bayer Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Zhejiang Medicine

      • 19.15.1 Zhejiang Medicine Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Hisun Pharmaceutical

      • 19.16.1 Hisun Pharmaceutical Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Huahai Pharmaceutical

      • 19.17.1 Huahai Pharmaceutical Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 AbbVie

      • 19.18.1 AbbVie Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 DSM

      • 19.19.1 DSM Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Harbin Pharmaceutical

      • 19.20.1 Harbin Pharmaceutical Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    The List of Tables and Figures (Totals 79 Figures and 130 Tables)

    • Figure Product Picture

    • Figure Active Pharmaceutical Ingredients Market Size and Growth Rate of Synthetic APIs Market, 2015 - 2026 (USD Million)

    • Figure Active Pharmaceutical Ingredients Market Size and Growth Rate of Biotech APIs Market, 2015 - 2026 (USD Million)

    • Figure Active Pharmaceutical Ingredients Market Size and Growth Rate of Hospitals/Clinics from 2014 to 2026

    • Figure Active Pharmaceutical Ingredients Market Size and Growth Rate of Household from 2014 to 2026

    • Figure Germany Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure UK Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure France Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Active Pharmaceutical Ingredients Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Active Pharmaceutical Ingredients Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Active Pharmaceutical Ingredients

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Active Pharmaceutical Ingredients by Different Types from 2014 to 2026

    • Table Consumption Share of Active Pharmaceutical Ingredients by Different Types from 2014 to 2026

    • Figure Active Pharmaceutical Ingredients Market Size and Growth Rate of Synthetic APIs Market, 2015 - 2026 (USD Million)

    • Figure Active Pharmaceutical Ingredients Market Size and Growth Rate of Biotech APIs Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Active Pharmaceutical Ingredients by Different End-Users from 2014 to 2026

    • Table Consumption Share of Active Pharmaceutical Ingredients by Different End-Users from 2014 to 2026

    • Figure Active Pharmaceutical Ingredients Market Size and Growth Rate of Hospitals/Clinics from 2014 to 2026

    • Figure Active Pharmaceutical Ingredients Market Size and Growth Rate of Household from 2014 to 2026

    • Table Europe Active Pharmaceutical Ingredients Production by Major Regions

    • Table Europe Active Pharmaceutical Ingredients Production Share by Major Regions

    • Figure Europe Active Pharmaceutical Ingredients Production Share by Major Countries and Regions in 2014

    • Table Europe Active Pharmaceutical Ingredients Consumption by Major Regions

    • Table Europe Active Pharmaceutical Ingredients Consumption Share by Major Regions

    • Table Germany Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table UK Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table France Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Italy Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Spain Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Poland Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Russia Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Switzerland Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Turkey Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Active Pharmaceutical Ingredients Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Active Pharmaceutical Ingredients Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Active Pharmaceutical Ingredients Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Active Pharmaceutical Ingredients Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Germany Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Germany Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Germany Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table France Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table France Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table France Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table France Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Active Pharmaceutical Ingredients Market Volume and Growth Rate from 2014 to 2026

    • Table Aurobindo Pharma Profiles

    • Table Aurobindo Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Aurobindo Pharma Product benchmarking

    • Table Aurobindo Pharma Strategic initiatives

    • Table Aurobindo Pharma SWOT analysis

    • Table Shandong Xinhua Pharmaceutical Profiles

    • Table Shandong Xinhua Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Shandong Xinhua Pharmaceutical Product benchmarking

    • Table Shandong Xinhua Pharmaceutical Strategic initiatives

    • Table Shandong Xinhua Pharmaceutical SWOT analysis

    • Table Northeast Pharm Profiles

    • Table Northeast Pharm Production, Value, Price, Gross Margin 2014-2019

    • Table Northeast Pharm Product benchmarking

    • Table Northeast Pharm Strategic initiatives

    • Table Northeast Pharm SWOT analysis

    • Table BASF Profiles

    • Table BASF Production, Value, Price, Gross Margin 2014-2019

    • Table BASF Product benchmarking

    • Table BASF Strategic initiatives

    • Table BASF SWOT analysis

    • Table Novartis Profiles

    • Table Novartis Production, Value, Price, Gross Margin 2014-2019

    • Table Novartis Product benchmarking

    • Table Novartis Strategic initiatives

    • Table Novartis SWOT analysis

    • Table LKPC Profiles

    • Table LKPC Production, Value, Price, Gross Margin 2014-2019

    • Table LKPC Product benchmarking

    • Table LKPC Strategic initiatives

    • Table LKPC SWOT analysis

    • Table Aspen Profiles

    • Table Aspen Production, Value, Price, Gross Margin 2014-2019

    • Table Aspen Product benchmarking

    • Table Aspen Strategic initiatives

    • Table Aspen SWOT analysis

    • Table Sun Pharmaceutical Industries Profiles

    • Table Sun Pharmaceutical Industries Production, Value, Price, Gross Margin 2014-2019

    • Table Sun Pharmaceutical Industries Product benchmarking

    • Table Sun Pharmaceutical Industries Strategic initiatives

    • Table Sun Pharmaceutical Industries SWOT analysis

    • Table Teva Profiles

    • Table Teva Production, Value, Price, Gross Margin 2014-2019

    • Table Teva Product benchmarking

    • Table Teva Strategic initiatives

    • Table Teva SWOT analysis

    • Table NCPC Profiles

    • Table NCPC Production, Value, Price, Gross Margin 2014-2019

    • Table NCPC Product benchmarking

    • Table NCPC Strategic initiatives

    • Table NCPC SWOT analysis

    • Table Pfizer Profiles

    • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

    • Table Pfizer Product benchmarking

    • Table Pfizer Strategic initiatives

    • Table Pfizer SWOT analysis

    • Table Mylan Profiles

    • Table Mylan Production, Value, Price, Gross Margin 2014-2019

    • Table Mylan Product benchmarking

    • Table Mylan Strategic initiatives

    • Table Mylan SWOT analysis

    • Table Zhejiang NHU Profiles

    • Table Zhejiang NHU Production, Value, Price, Gross Margin 2014-2019

    • Table Zhejiang NHU Product benchmarking

    • Table Zhejiang NHU Strategic initiatives

    • Table Zhejiang NHU SWOT analysis

    • Table Bayer Profiles

    • Table Bayer Production, Value, Price, Gross Margin 2014-2019

    • Table Bayer Product benchmarking

    • Table Bayer Strategic initiatives

    • Table Bayer SWOT analysis

    • Table Zhejiang Medicine Profiles

    • Table Zhejiang Medicine Production, Value, Price, Gross Margin 2014-2019

    • Table Zhejiang Medicine Product benchmarking

    • Table Zhejiang Medicine Strategic initiatives

    • Table Zhejiang Medicine SWOT analysis

    • Table Hisun Pharmaceutical Profiles

    • Table Hisun Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Hisun Pharmaceutical Product benchmarking

    • Table Hisun Pharmaceutical Strategic initiatives

    • Table Hisun Pharmaceutical SWOT analysis

    • Table Huahai Pharmaceutical Profiles

    • Table Huahai Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Huahai Pharmaceutical Product benchmarking

    • Table Huahai Pharmaceutical Strategic initiatives

    • Table Huahai Pharmaceutical SWOT analysis

    • Table AbbVie Profiles

    • Table AbbVie Production, Value, Price, Gross Margin 2014-2019

    • Table AbbVie Product benchmarking

    • Table AbbVie Strategic initiatives

    • Table AbbVie SWOT analysis

    • Table DSM Profiles

    • Table DSM Production, Value, Price, Gross Margin 2014-2019

    • Table DSM Product benchmarking

    • Table DSM Strategic initiatives

    • Table DSM SWOT analysis

    • Table Harbin Pharmaceutical Profiles

    • Table Harbin Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Harbin Pharmaceutical Product benchmarking

    • Table Harbin Pharmaceutical Strategic initiatives

    • Table Harbin Pharmaceutical SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.